Gabrielle Sebaratnam

Gabrielle Sebaratnam

Auto-generated profile, based on publicly available information

Gabrielle Sebaratnam

Alimetry Ltd

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2020 in International Journal of Social Robotics
Verified
Journal Article
Closed access
PDF file
KLKate Loveys
Kate Loveys
GSGabrielle Sebaratnam
Gabrielle Sebaratnam
MSMark Sagar
Mark Sagar
EBElizabeth Anne Broadbent
Elizabeth Anne Broadbent

13 February 2022 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
GSGabrielle Sebaratnam
Gabrielle Sebaratnam
NKNikita Karulkar
Nikita Karulkar
SCStefan Calder
Stefan Calder
JWJonathan S.T. Woodhead
Jonathan S.T. Woodhead
CKCelia Keane
Celia Keane
GOGreg O'Grady
Greg O'Grady
Background: Functional gastroduodenal disorders include functional dyspepsia, chronic nausea and vomiting syndromes, and gastroparesis. These disorders are common, but their overlapping symptomatology poses challenges to diagnosis, research, and therapy. This study aimed to introduce and validate a standardized patient symptom‐logging system and App to aid in the accurate reporting of gastroduodenal symptoms for clinical and research applications.Methods: The system was implemented in an iOS App including pictographic symptom illustrations, and two validation studies were conducted. To assess convergent and concurrent validity, a diverse cohort with chronic gastroduodenal symptoms undertook App‐based symptom logging for 4 h after a test meal. Individual and total post‐prandial symptom scores were averaged and correlated against two previously validated instruments: PAGI‐SYM (for convergent validity) and PAGI‐QOL (for concurrent validity). To assess face and content validity, semi‐structured qualitative interviews were conducted with patients.Key Results: App‐based symptom reporting demonstrated robust convergent validity with PAGI‐SYM measures of nausea (rS =0.68), early satiation (rS =0.55), bloating (rS =0.48), heartburn (rS =0.47), upper gut pain (rS =0.40), and excessive fullness (rS =0.40); all p < 0.001 (n = 79). The total App‐reported Gastric Symptom Burden Score correlated positively with PAGI‐SYM (rS =0.56; convergent validity; p < 0.001), and negatively with PAGI‐QOL (rS = −0.34; concurrent validity; p = 0.002). Interviews demonstrated that the pictograms had adequate face and content validity.Conclusions and Inferences: The continuous patient symptom‐logging App demonstrated robust convergent, concurrent, face, and content validity when used within a 4‐h post‐prandial test protocol. The App will enable standardized symptom reporting and is anticipated to provide utility in both research and clinical practice.

1 January 2020 in Technology, Mind, and Behavior
Verified
Journal Article
Open access
PDF file
DJDeborah L. Johanson
Deborah L. Johanson
Ho Seok AhnHo Seok Ahn
Ho Seok Ahn
JLJongYoon Lim
JongYoon Lim
CLChristopher Lee
Christopher Lee
GSGabrielle Sebaratnam
Gabrielle Sebaratnam
EBElizabeth Anne Broadbent
Elizabeth Anne Broadbent
As we approach a time in which social robots will be used in home and healthcare settings, there is a critical need to research robot behaviors that can increase user acceptance and comfort. The use of humor by physicians during patient interactions is associated with a number of positive patient health outcomes. However, no research to date has examined the effect of humor on user outcomes when used by a healthcare robot. This study examined the use of humor by a healthcare robot in a scripted interaction in a simulated medical setting. An experiment was conducted with 91 healthy participants (73 female, mean age 25 years). Participants were randomly allocated to interact with either a humorous or neutral robot in a flu vaccination scenario. Perceptions of the robot were assessed using the Godspeed questionnaire, an empathy questionnaire, and Asch personality scale, at two time points (before and after the interaction). Participant laughing was observed during the interaction. Repeated measures between group ANOVA showed that robot use of humor resulted in significantly greater perceptions of the robot’s likeability and safety. The humorous robot was also rated as having significantly more empathy, and a more sociable personality. Participants in the humorous condition were also more likely to rate the robot’s personality as happy, talkative, and frivolous, compared to participants in the neutral condition. Significantly more participants laughed during the interaction with the humorous robot, than with the neutral robot. Together, these findings suggest that the use of humor by a healthcare robot may increase positive user evaluations. This research has implications for both theory and clinical applications.

14 November 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CVChris Varghese
Chris Varghese
ALAlexandria Lim
Alexandria Lim
CDCharlotte Daker
Charlotte Daker
GSGabrielle Sebaratnam
Gabrielle Sebaratnam
AGArmen A. Gharibans
Armen A. Gharibans
GOGreg O'Grady
Greg O'Grady
INTRODUCTION: Gastroparesis is a debilitating gastroduodenal disorder for which gastric peroral endoscopic myotomy (GPOEM) has emerged as an efficacious treatment option. However, response to GPOEM varies between 50% and 80%, such that preoperative predictors of treatment success are needed to guide patient selection. METHODS: We performed a systematic review to identify predictors of clinical and functional response to GPOEM among adult patients with gastroparesis (PROSPERO: CRD42023457359). MEDLINE, Embase, and CENTRAL databases were searched systematically for studies reporting outcomes after GPOEM in September 2023. A narrative synthesis of predictive factors on univariable and multivariable analysis was performed with consideration of response rates through meta-analysis and evaluation of discrimination if prognostic models were developed. Risk Of Bias In Non-randomized Studies - of Exposures (ROBINS-E) was used for risk of bias assessment. RESULTS: Of 1899 articles reviewed, 30 were included. The GPOEM response rate was 63.1% (95% confidence interval 56.3%–69.5%) with most studies defining clinical success on the basis of improvement in gastroparesis cardinal symptom index (87%, 26/30). Older age, shorter duration of gastroparesis, nondiabetic etiology, lower body mass index, and response to intrapyloric botulinum toxin were associated with positive response to GPOEM on multivariable analyses. Predictors on physiological tests such as EndoFLIP or gastric emptying scintigraphy were inconsistent. No prognostic models underwent external validation. DISCUSSION: Currently, there are limited reproducible predictors of response to GPOEM among patients with refractory gastroparesis. Robust prospective studies investigating scalable, reproducible, and actionable biomarkers of treatment response are required.

30 April 2024 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
MLMikaela Law
Mikaela Law
Gabriel SchambergGabriel Schamberg
Gabriel Schamberg
AGArmen Gharibans
Armen Gharibans
GSGabrielle Sebaratnam
Gabrielle Sebaratnam
DFDaphne Foong
Daphne Foong
SCStefan Calder
Stefan Calder
Background: Many diagnostic tests for gastroduodenal symptoms, such as gastric emptying scintigraphy (GES), gastric emptying breath tests (GEBT), and electrogastrography (EGG) show variable intra‐individual reproducibility over time. This study investigated the short‐ and long‐term reproducibility of body surface gastric mapping (BSGM), a non‐invasive test for assessing gastric function, in controls and patients with chronic gastroduodenal disorders. Methods: Participants completed three standardized BSGM tests using Gastric Alimetry® (Alimetry, New Zealand). The test encompassed a fasting baseline (30 min), a 482 kCal standard meal, and a 4 h postprandial recording. The first two tests were >6 months apart and the last occurred ~1 week after the second test, to evaluate long and short‐term reproducibility. Results: Fourteen patients with upper gastrointestinal symptoms and 14 healthy controls were recruited. There were no significant differences in any BSGM metrics between the tests at short and long term (all p > 0.180). Lin's concordance correlation coefficients (CCC) for the primary metrics were high, ranging from 0.58 to 0.96, with intra‐individual coefficients of variance (CV intra ) ranging from 0.2% to 1.9%. Reproducibility was higher, and intra‐individual variation lower, than in previous studies of GES (CCC = 0.54–0.83, CV intra = 3%–77%), GEBT (CV intra = 8%–11%), and EGG (CV intra = 3%–78%). Conclusions: BSGM spectral metrics demonstrate high reproducibility and low intra‐individual variation at both short and long term, with superior results to comparable tests. The high reproducibility of Gastric Alimetry supports its role as a diagnostic aid for gastric dysfunction and a reliable tool for evaluating treatment outcomes and disease progression over time.

12 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
GSG Sebaratnam
G Sebaratnam
NKN Karulkar
N Karulkar
SCS Calder
S Calder
JWJst Woodhead
Jst Woodhead
CKC Keane
C Keane
GOGreg O'Grady
Greg O'Grady
Background: Functional gastroduodenal disorders include functional dyspepsia, chronic nausea and vomiting syndromes, and gastroparesis. These disorders are common, but their overlapping symptomatology poses challenges to diagnosis, research, and therapy. This study aimed to introduce and validate a standardized patient symptom-logging system and App to aid in the accurate reporting of gastroduodenal symptoms for clinical and research applications. Methods: The system was implemented in an iOS App including pictographic symptom illustrations, and two validation studies were conducted. To assess convergent and concurrent validity, a diverse cohort with chronic gastroduodenal symptoms undertook App-based symptom logging for 4-hours after a test meal. Individual and total post-prandial symptom scores were averaged and correlated against two previously validated instruments: PAGI-SYM (for convergent validity) and PAGI-QOL (for concurrent validity). To assess face and content validity, semi-structured qualitative interviews were conducted with patients. Key Results: App-based symptom reporting demonstrated robust convergent validity with PAGI-SYM measures of nausea ( r S =0.68), early satiation ( r S =0.55), bloating ( r S =0.48), heartburn ( r S =0.47), upper gut pain ( r S =0.40) and excessive fullness ( r S =0.40); all p<0 . 001 (n=79). The total App-reported Gastric Symptom Burden Score correlated positively with PAGI-SYM ( r S =0.56; convergent validity; p<0 . 001 ), and negatively with PAGI-QOL ( r S =-0.34; concurrent validity; p=0 . 002 ). Interviews demonstrated that the pictograms had adequate face and content validity. Conclusions and Inferences: The continuous patient symptom-logging App demonstrated robust convergent, concurrent, face, and content validity when used within a 4-hour post-prandial test protocol. The App will enable standardized symptom reporting and is anticipated to provide utility in both research and clinical practice.